Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer

BET bromodomain inhibitors (BBDI) are candidate therapeutic agents in triple-negative breast cancer (TNBC) and other cancer types, but inherent and acquired resistance to BBDIs limit their potential clinical use. Using CRISPR and small molecule inhibitor screens combined with comprehensive molecular...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cell
Hauptverfasser: Shu, Shaokun, Wu, Hua-Jun, Ge, Jennifer Y., Zeid, Rhamy, Harris, Isaac S., Jovanović, Bojana, Murphy, Katherine, Wang, Binbin, Qiu, Xintao, Endress, Jennifer E., Reyes, Jaime, Lim, Klothilda, Font-Tello, Alba, Syamala, Sudeepa, Xiao, Tengfei, Reddy Chilamakuri, Chandra Sekhar, Papachristou, Evangelia K., D’Santos, Clive, Anand, Jayati, Hinohara, Kunihiko, Li, Wei, McDonald, Thomas O., Luoma, Adrienne, Modiste, Rebecca J., Nguyen, Quang-De, Michel, Brittany, Cejas, Paloma, Kadoch, Cigall, Jaffe, Jacob D., Wucherpfennig, Kai W., Qi, Jun, Liu, X. Shirley, Long, Henry, Brown, Myles, Carroll, Jason S., Brugge, Joan S., Bradner, James, Michor, Franziska, Polyak, Kornelia
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306005/
https://ncbi.nlm.nih.gov/pubmed/32416067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molcel.2020.04.027
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge